- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04861181
NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients. (NIRAPK)
Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment (300mg or 200 mg/Day) for Ovarian Cancer Patients.
Ovarian cancer is the seventh most common cancer in women worldwide and is the leading cause of gynecologic cancer deaths in high-income countries.
Standard treatment for newly diagnosed advanced ovarian cancer consist of cytoreductive surgery and platinum-based chemotherapy with or without concurrent and maintenance bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor.
A majority of women with epithelial ovarian cancer respond well to first-line platinum-based chemotherapy. There is however a high rate of relapse/recurrence (disease progression ranging from 10 to 26 months).
Poly ADP ribose polymerase inhibitors (PARPi), a new class of therapeutic molecules have recently revolutionized this paradigm, demonstrating progression-free survival (PFS) advantages in several trials.
The PARPi molecule Niraparib has obtained its market authorization after the NOVA trial as second maintenance treatment line, irrespectively of patients' BRCA-mutated gene or HR status.
Since, results of the Phase III trial PRIMA, have demonstrated that Niraparib can also provided a significant PFS increase as first line maintenance treatment, for adult patients with platinum-sensitive, relapsed, high grade serous epithelial ovarian cancer who are in response (complete response or partial response) to platinum-based chemotherapy, irrespectively of their BRCA-mutated gene or HR status.
However, despite its high therapeutic potential, Niraparib at standard dose (200 or 300mg/day) is known to lead to hematologic toxicity and/or nephrotoxicity. This was demonstrated during the NOVA trial (the dose of Niraparib having to be reduced in 80% of the patients to reduce toxicity).
A retrospective study of the NOVA trial indicates that 2 predictive factors leading to hematologic toxicity were a weight <77kg and an initial platelet count <175 G/L. However, it seems more complex as 50% of patients with an initial weight between 58 and 77kg have not reported thrombocytopenia. Same for platelet count. Creatinine clearance below 60ml/min and an hypoalbuminemia <35 g/l have also been identified in another study as predictive factors to thrombocytopenia.
The inter-individual heterogeneity in terms of toxicity regarding Niraparib is high and still not well understood.
The aim of our study is therefore to better identify which clinical, biological and pharmacokinetic metrics can be considered as toxicity induction causes when Niraparib is used as maintenance treatment (200 or 300mg/day) for ovarian cancer patients.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Benoit YOU, MD, PhD
- Phone Number: +33 478864318
- Email: benoit.you@chu-lyon.fr
Study Locations
-
-
-
Pierre-Bénite, France, 69495
- Recruiting
- Hôpital Lyon sud, Institut de Cancérologie des Hospices Civils de Lyon
-
Principal Investigator:
- Benoit You
-
Contact:
- Benoit YOU
- Phone Number: 04.78.86.43.18
- Email: benoit.you@chu-lyon.fr
-
Contact:
- Anne Sophie BELMONT
- Email: anne-sophie.belmont@chu-lyon.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient Study Information and written informed consent
- Social Security Affiliation
- Patient > 18 years old.
- Ovarian, tubular or peritoneal high-grade epithelial carcinoma, histologically proven. Recommendation of a maintenance treatment with Niraparib at standard dose (200-300mg/day)
- Glomerular filtration rate with standardized serum creatinine values using CKD-EPI formula ≥ 30ml/min/1.73m2 (https://www.kidney.org/professionals/kdoqi/gfr_calculator)
- Normal liver function with bilirubin < 1.5N
- 6-8 weeks break between last chemotherapy and Niraparib treatment initiation.
- Patient with an effective birth control
Exclusion Criteria:
- Minor patient
- Patient not able to understand the aim of the study or under curatorship
- Low grade carcinoma
- Pregnant or breastfeeding patient
- Hypersensivity to an active substance present in niraparib
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pharmacokinetics, Dosage of Niraparib
Patients received 3 cycles of Niraparib (200 mg or 300 mg/day).
Each cycle lasts 28 days.
Serum niraparib assays will be performed for all patients over 3 courses immediately prior to treatment (Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and Cycle 3 Day 1).
Close-up kinetic measurements will also be taken at 1 Hour, 2 Hours, 4 Hours, 6 Hours and 24 Hours at Cycle 1 Day 15.
|
The biological samples collected during the NIRAPK study will be blood only.
The complete biological work-up will be processed in the same way as the usual routine care procedure.
Serum niraparib will be measured over 3 courses just prior to treatment (Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and Cycle 3 Day 1).
Close-up kinetic measurements will also be taken at 1 Hour, 2 Hours, 4 Hours, 6 Hours and 24 Hours at Cycle 1 Day 15.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identification of metrics (clinical, biological, pharmacokinetic) that are considered as toxicity induction causes (hematological toxicity or nephrotoxicity)
Time Frame: Month 10; after all the blood sample collection is achieved for all included patients.
|
Blood will be sampled at Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and Cycle 3 Day 1 and based on the obtained results, it will be seek if a link can be established between the clinical, biological and pharmacokinetic metrics and the observed toxicity.
|
Month 10; after all the blood sample collection is achieved for all included patients.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determination of the average pharmacokinetic metrics observed in our study panel patients.
Time Frame: Month 10; after all the blood sample collection is achieved for all included patients..
|
Blood will be sampled at Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and Cycle 3 Day 1 and based on the obtained results, the average metrics of pharmacokinetic parameters will be determined.
|
Month 10; after all the blood sample collection is achieved for all included patients..
|
Relationship between the pharmacokinetic metrics and the PFS at 24 months.
Time Frame: Month 34; after last patient inclusion (Month 10) + 24 months.
|
Blood will be sampled at Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and Cycle 3 Day 1 and based on the obtained results, it will be determined if a link can be established between the pharmacokinetic metrics and the PFS at 24 months
|
Month 34; after last patient inclusion (Month 10) + 24 months.
|
Relationship between the quality of life and the observed toxicity assessed by the "EORTC OVARIAN" questionnaire
Time Frame: Month 10, after last patient enrolment.
|
Analysis of quality of life by "QLQ OV28" questionnaire score collected at Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and Cycle 3 Day 1 and observed toxicity.
|
Month 10, after last patient enrolment.
|
Relationship between the quality of life and the observed toxicity assessed by the "Charlson Score" questionnaire
Time Frame: Month 10, after last patient enrolment.
|
Analysis of quality of life by "Charlson Score" questionnaire score collected at Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and Cycle 3 Day 1 and observed toxicity.
|
Month 10, after last patient enrolment.
|
Relationship between the quality of life and the observed toxicity assessed by the "Assessment of polymedication" questionnaire
Time Frame: Month 10, after last patient enrolment.
|
Analysis of quality of life by "Assessment of polymedication" questionnaire score collected at Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and Cycle 3 Day 1 and observed toxicity.
|
Month 10, after last patient enrolment.
|
Relationship between the quality of life and the observed toxicity assessed by the "Recording of food intake and monitoring of eating habits" questionnaire
Time Frame: Month 10, after last patient enrolment.
|
Analysis of quality of life by "Recording of food intake and monitoring of eating habits" questionnaire score collected at Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and Cycle 3 Day 1 and observed toxicity.
|
Month 10, after last patient enrolment.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Poly(ADP-ribose) Polymerase Inhibitors
- Niraparib
Other Study ID Numbers
- 69HCL20_0989
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adult Patients With Platinum-sensitive, Relapsed, High Grade Serous Epithelial Ovarian Cancer
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Malignant Ovarian Endometrioid Tumor | Ovarian High Grade Serous Adenocarcinoma | Platinum-Sensitive Ovarian Carcinoma | Fallopian Tube High Grade Serous Adenocarcinoma and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingRecurrent Primary Peritoneal High Grade Serous Adenocarcinoma | High Grade Ovarian Serous Adenocarcinoma | Recurrent High Grade Fallopian Tube Serous Adenocarcinoma | Recurrent High Grade Ovarian Serous Adenocarcinoma | High Grade Fallopian Tube Serous Adenocarcinoma | Peritoneal High Grade...United States
-
Emory UniversityNational Cancer Institute (NCI)RecruitingOvarian High Grade Serous Adenocarcinoma | Platinum-Resistant Ovarian CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingOvarian Endometrioid Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Ovarian High Grade Serous Adenocarcinoma | Platinum-Resistant... and other conditionsUnited States, Canada
-
National Cancer Institute (NCI)NRG OncologyWithdrawnRecurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent Ovarian Endometrioid Adenocarcinoma | Recurrent Platinum-Resistant Fallopian Tube Carcinoma | Recurrent Platinum-Resistant Primary... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Breast Carcinoma | Metastatic Triple-Negative Breast Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Recurrent... and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian CarcinomaUnited States
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingOvarian Seromucinous Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Fallopian Tube Mucinous Adenocarcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent... and other conditionsUnited States, Puerto Rico
-
Aprea TherapeuticsCompletedPlatinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53United States, France, Spain, Netherlands, United Kingdom, Belgium, Germany, Sweden
-
AstraZenecaISTITUTO REGINA ELENA - CENTRO RICERCHE SPERIMENTALITerminatedPatients With Advanced Ovarian Cancer Sensitive to Platinum-based ChemotherapyItaly, Germany
Clinical Trials on Pharmacokinetics, Dosage of Niraparib
-
Assistance Publique - Hôpitaux de ParisRecruitingJuvenile DermatomyositisFrance
-
Universidad Autonoma de MadridUnknown
-
Tesaro, Inc.Completed
-
Tesaro, Inc.Active, not recruiting
-
Virginia Commonwealth UniversityGlaxoSmithKline; Puma Biotechnology, Inc.RecruitingOvarian Cancer | Advanced Solid TumorUnited States
-
Fudan UniversityRecruitingTreatment EfficacyChina
-
Université Victor Segalen Bordeaux 2CompletedVentilated-acquired PneumoniaFrance
-
Assistance Publique - Hôpitaux de ParisUnknown
-
University Of PerugiaRecruiting
-
Jiangsu Province Centers for Disease Control and...RecruitingCOVID-19 | Pulmonary TuberculosisChina